Claims for Patent: 9,725,444

Summary for Patent: 9,725,444

Title:	Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
Abstract:	Compounds as inhibitors of CSCPK and related kinases. The compounds are thiazole-substituted indolin-2-ones and are prepared from indolin-2-ones. They are included in pharmaceutical compositions and both the compounds and the pharmaceutical compositions are used in inhibiting cancer stem cells and in the treatment of a protean kinase related disorders.
Inventor(s):	Li; Chiang Jia (Cambridge, MA), Liu; Ji-Feng (Winchester, MA), Li; Youzhi (Westwood, MA), Li; Wei (Wayland, MA), Rogoff; Harry (Wrentham, MA)
Assignee:	BOSTON BIOMEDICAL, INC (Cambridge, MA)
Application Number:	14/445,783
Patent Claims:	1. A compound of formula IV, ##STR00024## or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols have the following meanings and axe, for each occurrence, independent selected: R.sub.1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR.sub.a, SR.sub.a, S(.dbd.O).sub.2R.sub.e, S(.dbd.O).sub.2OR.sub.e, C(.dbd.O)OR.sub.d, C(.dbd.O)R.sub.a, or C(.dbd.O)NR.sub.bR.sub.c; R.sub.3 and R.sub.10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R.sub.4, R.sub.7, and R.sub.8 are each independently hydrogen, halogen, cyano nitro, CF.sub.3, OCF.sub.3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR.sub.a, SR.sub.a, S(.dbd.O)R.sub.e, S(.dbd.O).sub.2R.sub.e, P(.dbd.O).sub.2R.sub.e, S(.dbd.).sub.2OR.sub.e, P(.dbd.O).sub.2OR.sub.e, NR.sub.bR.sub.c, NR.sub.bS(.dbd.O).sub.2R.sub.e, NR.sub.bP(.dbd.O).sub.2R.sub.e, S(.dbd.O).sub.2NR.sub.bR.sub.c, P(.dbd.O).sub.2NR.sub.bR.sub.c, C(.dbd.O)OR.sub.e, C(.dbd.O)R.sub.a, C(.dbd.O)NR.sub.bR.sub.c, OC(.dbd.O)R.sub.a, OC(.dbd.O)NR.sub.bR.sub.c, NR.sub.bC(.dbd.O)OR.sub.e, NR.sub.dC(.dbd.O)NR.sub.bR.sub.c, NR.sub.dS(.dbd.O).sub.2NR.sub.bR.sub.c, NR.sub.dP(.dbd.O).sub.2NR.sub.bR.sub.c, NR.sub.bC(.dbd.O)R.sub.a, or NR.sub.bP(.dbd.O).sub.2R.sub.e; R.sub.5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R.sub.8 and R.sub.9 are each independently hydrogen, halogen, cyano, nitro, CF.sub.3, OCF.sub.3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR.sub.a; R.sub.14 and R.sub.15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R.sub.14 and R.sub.15 together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; R.sub.a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R.sub.b, R.sub.c and R.sub.d are independently hydrogen, alkyl or substituted alkyl cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R.sub.b and R.sub.c together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; and R.sub.e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl. 2. A compound of formula V, ##STR00025## or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols have the following meanings and are, for each occurrence, independently selected: R.sub.1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR.sub.a, SR.sub.a, S(.dbd.O).sub.2R.sub.e, S(.dbd.O).sub.2OR.sub.e, C(.dbd.O)OR.sub.d, C(.dbd.O)R.sub.a, or C(.dbd.O)NR.sub.bR.sub.c; R.sub.3 and R.sub.10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R.sub.4, R.sub.7, and R.sub.8 are each independently hydrogen, halogen, cyano, nitro, CF.sub.3, OCF.sub.3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR.sub.a, SR.sub.a, S(.dbd.O)R.sub.e, S(.dbd.O).sub.2R.sub.e, P(.dbd.O).sub.2R.sub.e, S(.dbd.O).sub.2OR.sub.e, P(.dbd.O).sub.2OR.sub.e, NR.sub.bR.sub.c, NR.sub.bS(.dbd.O).sub.2R.sub.e, NR.sub.bP(.dbd.O).sub.2R.sub.e, S(.dbd.O).sub.2NR.sub.bR.sub.c, P(.dbd.O).sub.2NR.sub.bR.sub.c, C(.dbd.O)OR.sub.e, C(.dbd.O)R.sub.a, C(.dbd.O)NR.sub.bR.sub.c, OC(.dbd.O)R.sub.a, OC(.dbd.O)NR.sub.bR.sub.c, NR.sub.bC(.dbd.O)OR.sub.e, NR.sub.dC(.dbd.O)NR.sub.bR.sub.c, NR.sub.dS(.dbd.O).sub.2NR.sub.bR.sub.c, NR.sub.dP(.dbd.O).sub.2NR.sub.bR.sub.c, NR.sub.bC(.dbd.O)R.sub.a, or NR.sub.bP(.dbd.O).sub.2R.sub.e; R.sub.5 is substituted alkyl, heterocycle or substituted, heterocycle, aryl or substituted aryl; R.sub.8 and R.sub.9 each independently hydrogen, halogen, cyano, nitro, CF.sub.3, OCF.sub.3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR.sub.a; R.sub.11 is hydrogen or C.sub.1-4 alkyl; R.sub.12 and R.sub.13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R.sub.12 and R.sub.13 together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; n is an integer selected from 2, 3, 4, 5 and 6; R.sub.a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R.sub.b, R.sub.c and R.sub.d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or said R.sub.b and R.sub.c together with the N to which they are bonded optionally form a heterocycle or substituted heterocycle; and R.sub.e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl. 3. The compound of claim 2, wherein R.sub.1, R.sub.3, R.sub.4, R.sub.6, R.sub.7, R.sub.8 and R.sub.11 are each independently hydrogen. 4. The compound of claim 3, wherein R.sub.9 and R.sub.10 are each independently methyl, and n is 2. 5. The compound of claim 4, wherein R.sub.12 and R.sub.13 are independently hydrogen, C.sub.1-4 alkyl or substituted C.sub.1-4 alkyl, or said R.sub.12 and R.sub.13 together with the N to which they are bonded optionally form a 3-membered, 4-membered, 5-membered, 6-membered, or 7-membered saturated substituted or unsubstituted heterocycle. 6. The compound of claim 5, wherein R.sub.5 is alkylaryl or alkylheteroaryl, in which said alkyl, aryl or heteroaryl may be optionally substituted. 7. The compound of claim 5, wherein R.sub.5 is aryl or substituted aryl. 8. The compound of claim 5, wherein R.sub.5 is heteroaryl or substituted heteroaryl. 9. The compound of claim 5, wherein R.sub.5 is phenyl or substituted phenyl. 10. A pharmaceutical composition comprising the compound or a pharmaceutically-acceptable salt thereof as claimed in claim 2 and a pharmaceutically-acceptable excipient, carrier, or diluent. 11. A method of treating cancer in a mammal, comprising administering to one mammal in need thereof a therapeutically effective amount of the compound as claimed in claim 2. 12. The method of claim 11, wherein the cancer is selected from the group consisting of lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, non-small cell lung cancer, genitourinary cancer, pancreatic cancer, thyroid cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, gastrointestinal cancer, gastric cancer, hepatoma, gastrointestinal stromal tumor, squamous cell carcinoma, renal cell carcinoma, astrocytoma, Kaposi's sarcoma, chronic myelogenous leukemia, acute myelogenous leukemia, myeloproliferative disorders, and glioblastoma. 13. A method of treating hepatocellular cancer (HCC) cancer in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound as claimed in claim 2. 14. A method of inhibiting/reducing/diminishing cancer stem cell survival and/or proliferation in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound as claimed in claim 2. 15. A method of treat ng metastatic cancer in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound as claimed in claim 2. 16. The pharmaceutical composition of claim 10, further comprising at least one other anti-cancer therapy agent. 17. The pharmaceutical composition of claim 16, wherein said anti-cancer therapy agent is at least one agent selected from the group consisting of radiotherapy (XRT) agents, cytotoxic agents, targeted agents, and adjunctive agents. 18. The pharmaceutical composition of claim 17, wherein said anti-cancer therapy agent is selected from gemcitabine, erlotinib, paclitaxel/docetaxel, carboplatin, cisplatin, fluorouracil (5-FU), doxorubicin, sorafenib, imatinib, bevacizumab, cetuximab, and trastuzumab.

Details for Patent 9,725,444

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26